192 related articles for article (PubMed ID: 36066011)
1. Class IV semaphorins in disease pathogenesis.
Nojima S
Pathol Int; 2022 Oct; 72(10):471-487. PubMed ID: 36066011
[TBL] [Abstract][Full Text] [Related]
2. The potential of class 3 semaphorins as both targets and therapeutics in cancer.
Mishra R; Kumar D; Tomar D; Chakraborty G; Kumar S; Kundu GC
Expert Opin Ther Targets; 2015 Mar; 19(3):427-42. PubMed ID: 25434284
[TBL] [Abstract][Full Text] [Related]
3. The semaphorins and their receptors as modulators of tumor progression.
Neufeld G; Mumblat Y; Smolkin T; Toledano S; Nir-Zvi I; Ziv K; Kessler O
Drug Resist Updat; 2016 Nov; 29():1-12. PubMed ID: 27912840
[TBL] [Abstract][Full Text] [Related]
4. Plexin-a4 mediates axon-repulsive activities of both secreted and transmembrane semaphorins and plays roles in nerve fiber guidance.
Suto F; Ito K; Uemura M; Shimizu M; Shinkawa Y; Sanbo M; Shinoda T; Tsuboi M; Takashima S; Yagi T; Fujisawa H
J Neurosci; 2005 Apr; 25(14):3628-37. PubMed ID: 15814794
[TBL] [Abstract][Full Text] [Related]
5. The role of semaphorins in cardiovascular diseases: Potential therapeutic targets and novel biomarkers.
Yin Z; Zhang J; Xu S; Liu J; Xu Y; Yu J; Zhao M; Pan W; Wang M; Wan J
FASEB J; 2022 Oct; 36(10):e22509. PubMed ID: 36063107
[TBL] [Abstract][Full Text] [Related]
6. The role of the semaphorins in cancer.
Neufeld G; Mumblat Y; Smolkin T; Toledano S; Nir-Zvi I; Ziv K; Kessler O
Cell Adh Migr; 2016 Nov; 10(6):652-674. PubMed ID: 27533782
[TBL] [Abstract][Full Text] [Related]
7. Class-3 Semaphorins and Their Receptors: Potent Multifunctional Modulators of Tumor Progression.
Toledano S; Nir-Zvi I; Engelman R; Kessler O; Neufeld G
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30696103
[No Abstract] [Full Text] [Related]
8. Semaphorins in angiogenesis and tumor progression.
Neufeld G; Sabag AD; Rabinovicz N; Kessler O
Cold Spring Harb Perspect Med; 2012 Jan; 2(1):a006718. PubMed ID: 22315716
[TBL] [Abstract][Full Text] [Related]
9. Semaphorins in cancer.
Neufeld G; Shraga-Heled N; Lange T; Guttmann-Raviv N; Herzog Y; Kessler O
Front Biosci; 2005 Jan; 10():751-60. PubMed ID: 15569615
[TBL] [Abstract][Full Text] [Related]
10. Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer.
Mastrantonio R; You H; Tamagnone L
Theranostics; 2021; 11(7):3262-3277. PubMed ID: 33537086
[TBL] [Abstract][Full Text] [Related]
11. Semaphorin signaling in vascular and tumor biology.
Neufeld G; Lange T; Varshavsky A; Kessler O
Adv Exp Med Biol; 2007; 600():118-31. PubMed ID: 17607951
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of class-3 semaphorins and their neuropilin receptors in oncology.
Nasarre P; Gemmill RM; Drabkin HA
Onco Targets Ther; 2014; 7():1663-87. PubMed ID: 25285016
[TBL] [Abstract][Full Text] [Related]
13. Class 3 semaphorins and their receptors in physiological and pathological angiogenesis.
Staton CA
Biochem Soc Trans; 2011 Dec; 39(6):1565-70. PubMed ID: 22103488
[TBL] [Abstract][Full Text] [Related]
14. Diverse roles for semaphorin-plexin signaling in the immune system.
Takamatsu H; Kumanogoh A
Trends Immunol; 2012 Mar; 33(3):127-35. PubMed ID: 22325954
[TBL] [Abstract][Full Text] [Related]
15. Full-Length Semaphorin-3C Is an Inhibitor of Tumor Lymphangiogenesis and Metastasis.
Mumblat Y; Kessler O; Ilan N; Neufeld G
Cancer Res; 2015 Jun; 75(11):2177-86. PubMed ID: 25808871
[TBL] [Abstract][Full Text] [Related]
16. Semaphorins and their Signaling Mechanisms.
Alto LT; Terman JR
Methods Mol Biol; 2017; 1493():1-25. PubMed ID: 27787839
[TBL] [Abstract][Full Text] [Related]
17. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B.
Basile JR; Barac A; Zhu T; Guan KL; Gutkind JS
Cancer Res; 2004 Aug; 64(15):5212-24. PubMed ID: 15289326
[TBL] [Abstract][Full Text] [Related]
18. Semaphorins and tumor angiogenesis.
Serini G; Maione F; Giraudo E; Bussolino F
Angiogenesis; 2009; 12(2):187-93. PubMed ID: 19266292
[TBL] [Abstract][Full Text] [Related]
19. Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells.
Kigel B; Varshavsky A; Kessler O; Neufeld G
PLoS One; 2008 Sep; 3(9):e3287. PubMed ID: 18818766
[TBL] [Abstract][Full Text] [Related]
20. Semaphorin signaling in bone.
Verlinden L; Vanderschueren D; Verstuyf A
Mol Cell Endocrinol; 2016 Sep; 432():66-74. PubMed ID: 26365296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
